Absorption, distribution, metabolism, and excretion considerations in selection of orally active indole-containing endothelin antagonist

Drug Metabolism and Disposition

Volumn 29, Issue 11, 2001, Pages 1424-1431

  Walker, Donald K ^a   Dack, Kevin N ^a   Dickinson, Roger P ^a   Fenner, Katherine S ^a   James, Kim ^a   Rawson, David J ^a   Smith, Dennis A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [1 (1,3 BENZODIOXOL 5 YL) 2 [(2 METHOXY 4 METHYLPHENYL)SULFONAMIDO] 2 OXOETHYL] 6 (CARBOXY) 1 METHYL 1H INDOLE; 3 [1 (1,3 BENZODIOXOL 5 YL) 2 [(2 METHOXY 4 METHYLPHENYL)SULFONAMIDO] 2 OXOETHYL] 6 (HYDROXYMETHYL) 1 METHYL 1H INDOLE; DRUG METABOLITE; ENDOTHELIN RECEPTOR ANTAGONIST; INDOLE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CALCULATION; CELL STRAIN CACO 2; CONTROLLED STUDY; DOG; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; DRUG METABOLISM; DRUG PENETRATION; DRUG STRUCTURE; FEMALE; HUMAN; HUMAN CELL; HYDROGEN BOND; MALE; MONOLAYER CULTURE; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES DIFFERENCE; STRUCTURE ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; CACO-2 CELLS; DOGS; ENDOTHELIN-1; FEMALE; HUMANS; INDOLES; INTESTINAL ABSORPTION; MALE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, ENDOTHELIN A; RECEPTORS, ENDOTHELIN; SPECIES SPECIFICITY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0034771889     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Functional group contributions to drug-receptor interactions
2. Caco-2 monolayers in experimental and theoretical predictions of drug transport
3. 2 antagonist in rat, dog and man
4. How structural features influence the biomembrane permeability of peptides
5. Physicochemical and drug-delivery considerations for oral drug bioavailability
6. Endothelin receptor antagonists and their developing role in cardiovascular therapeutics
7. 2 receptor antagonists in the isolated perfused rat liver
8. Desolvation energy: A major determinant of absorption but not clearance, of peptides in rats
9. Novel neurohormonal modulators in cardiovascular disorders. The therapeutic potential of endopeptidase inhibitors
10. Theoretical considerations on two equations for estimating the extent of absorption after oral administration of drugs
11. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings
12. Pathophysiology of endothelin in the cardiovascular system
13. Drug concentration response relationships in normal volunteers after oral administration of Iosartan, an angiotensin II receptor antagonist
14. Hydrogen bond strength estimation by means of the HYBOT program package
15. Complete thermodynamic description of H-bonding in the framework of multiplicative approach
16. A antagonists
17. Design of drugs involving the concepts and theories of drug metabolism and pharmacokinetics
18. An improved method for the determination of distribution coefficients
19. Estimation of Caco-2 permeability using calculated molecular descriptors
20. Property-based design: Optimization of drug absorption and pharmacokinetics
21. Azole endothelin antagonists. 3. Using Δ log P as a tool to improve absorption
22. Pharmacokinetics and metabolism of sildenafil in mouse, rat, rabbit, dog and man
23. Sarafotoxin S6c: An agonist which distinguishes between endothelin receptor subtypes
24. Pharmacology of L-754,142, a highly potent, orally active, nonpeptidyl endothelin antagonist
25. Losartan, an orally active nonpeptide angiotensin II receptor antagonist
26. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - Fact or myth